684 patents
Page 6 of 35
Utility
Methods of Using Heterocyclic Compounds As DELTA-5 Desaturase Inhibitors
25 May 23
Jennifer R. ALLEN, Michela BELTRANI, Matthew P. BOURBEAU, Teodora P. DAMYANOVA, Iain LINGARD, Ana E. MINATTI, Paolo Vincetti
Filed: 18 Nov 22
Utility
Process for Manipulating the Level of Glycan Content of a Glycoprotein
25 May 23
The present invention provides a method for manipulating the fucosylated glycan content on a recombinant protein.
Daniel R. LEISKE, Michael T. TRENTALANGE
Filed: 18 Jan 23
Utility
ANTI-STEAP1 Antigen-binding Protein
25 May 23
The disclosure provides novel antigen-binding proteins that bind STEAP1 and methods of use.
Olivier Nolan-Stevaux, Cong Li, Christopher M. Murawsky, Benjamin M. Alba, Neeraj Jagdish Agrawal, Kevin Graham, Jennitte LeAnn Stevens
Filed: 10 Nov 22
Utility
Anti-tnf Alpha Antibody Formulations
18 May 23
Stable adalimumab formulations are disclosed.
William J. CALLAHAN, Rahul Rajan KAUSHIK, Joy BRENNAN
Filed: 19 Aug 22
Utility
Methods of Treating Heart Failure with Cardiac Sarcomere Activators
18 May 23
Provided herein are methods of treating a subject with heart failure, comprising administering to the subject an initial dose of a cardiac sarcomere activator (CSA) for an initial time period, and subsequently administering to the subject a dose of the CSA based on the subject's plasma concentration of the CSA at the end of the initial time period.
Narimon HONARPOUR, Fady Malik
Filed: 17 Jan 23
Utility
KIF18A Inhibitors for Treatment of Neoplastic Diseases
18 May 23
Provided herein are methods of treating a subject having a neoplastic disease, comprising administering to the subject a KIF18A inhibitor in an amount effective to treat the neoplastic disease a neoplastic disease in a subject.
Marc Noel PAYTON
Filed: 13 Apr 21
Utility
6-5 FUSED RINGS AS C5a INHIBITORS
18 May 23
Pingchen FAN, Christopher W. LANGE, Rebecca M. LUI, Viengkham MALATHONG, Venkat Reddy MALI, Sreenivas PUNNA, Rajinder SINGH, Hiroko TANAKA, Yibin ZENG, Penglie ZHANG
Filed: 3 May 22
Utility
Growth Differentiation Factor 15 Fusion Proteins
11 May 23
GDF15 molecules are provided herein.
YuMei XIONG, Kenneth William WALKER, Murielle Marie VENIANT ELLISON
Filed: 8 Apr 19
Utility
Selecting Chromatography Parameters for Manufacturing Therapeutic Proteins
11 May 23
In a method for facilitating selection of chromatography parameters for manufacturing a therapeutic protein, one or more process parameter values associated with a hypothetical chromatography process, and one or more molecular descriptors descriptive of the therapeutic protein, are received.
Or Dan, Roger Hart, Hann-Chung Wong
Filed: 21 Apr 21
Utility
Fixtures for Testing Elasticity of Drug Delivery Members and Related Methods
11 May 23
Fixtures for testing elasticity of drug related methods and related methods are disclosed.
Daniel Coller, Jahangir Ashraf, Robert W. Swift, Oscar Rosas
Filed: 22 Apr 21
Utility
Heterocyclic Compounds As Triggering Receptor Expressed on Myeloid CELLS2 Agonists and Methods of Use
11 May 23
Lara C. CZABANIUK, Timothy HOPPER, Jonathan B. HOUZE, Gwenaella RESCOURIO, Vincent SANTORA, Haoxuan WANG, Ryan D. WHITE, Alice R. WONG, Yongwei WU
Filed: 30 Nov 22
Utility
Method for Treatment and Prophylaxis of CRS In Patients Comprising a Combination of Bispecific Antibodies Binding to CDS X Cancer Cell and TNF Alpha or IL-6 Inhibitor
11 May 23
The present invention relates to medical combination products comprising (i) at least one antibody construct comprising at least one domain which binds to a target antigen expressed on the surface of a cell and at least one other domain which binds to CD3 as well as (ii) at least one molecule that is inhibitor/antagonist of TNF/TNFR reducing TNF/TNFR signaling and/or an inhibitor/antagonist of IL6/IL6R that reduces IL6/IL6R signaling, wherein a first dose of said inhibitor/antagonist is administered before administration of a first dose of said antibody construct.
Sophia K. Khaldoyanidi, Dirk Nagorsen, Tara Arvedson, Suresh Agarwal, Vijay Vishesh Upreti, Steven Yea
Filed: 12 Mar 21
Utility
Methods of Treating Graft Versus Host Disease Using IL-2 Muteins
4 May 23
Described herein are immunosuppressive molecules including immunosuppressive variants of IL-2, and use of such molecules to treat inflammatory and autoimmune disorders.
Marc A. GAVIN, Li LI
Filed: 20 Dec 22
Utility
Sheet Lighting for Particle Detection in Drug Product Containers
4 May 23
In a method for imaging a container holding a sample, the container is illuminated with a laser sheet of a first color, and one or more images of the container are capturing by a first imager configured to filter out colors other than the first color.
Thomas Clark Pearson, Graham F. Milne, Dmitry Fradkin, Erwin Freund
Filed: 27 Dec 22
Utility
Synthesis of vinylic alcohol intermediates
4 May 23
Provided herein are processes for synthesizing intermediates useful in preparing Mcl-1 inhibitors.
Robert P. FARRELL, Jason S. TEDROW
Filed: 28 Apr 21
Utility
Packaging Label
4 May 23
A carton closure label is provided.
Diogo Ferreira
Filed: 30 Mar 21
Utility
Bispecific or Biparatopic Antigen Binding Proteins and Uses Thereof
4 May 23
The present invention relates to bispecific or biparatopic antigen binding proteins, polynucleotides encoding the same, and methods of making bispecific or biparatopic antigen binding proteins.
Wei YAN, Zhi LIU, Christopher MURAWSKY, Chadwick Terence KING, Yang LI, Zhonghua HU, Desiree LIM
Filed: 14 Nov 17
Utility
Torque Driven Drug Delivery Device
4 May 23
An injector includes a housing having a syringe assembly and an actuating mechanism at least partially disposed within the housing.
Adam B. McCullough, Ronald Forster, Joseph Michael Iglesias, Matias Melander, Rasmus Øhelschlaeger, Christian Plambech, Lars Stenholt, Bjarke Lykke Ludvig Svendsen
Filed: 4 Jun 18
Utility
Aryl Sulfonyl (Hydroxy) Piperidines as CCR6 Inhibitors
4 May 23
Penglie ZHANG, Daniel R. MARSHALL, Howard S. ROTH, Aubrie HARLAND, Ju YANG, Christopher W. LANGE, Rebecca M. LUI, Antoni KRASINSKI
Filed: 17 Aug 22
Utility
Proteins Specific for Baff and B7RP1 and Uses Thereof
27 Apr 23
Described herein are bispecific proteins specific for BAFF and B7RP1, nucleic acids encoding such proteins, methods of making such proteins, and uses for such proteins.
Hailing HSU, Ming ZHANG, Gunasekaran KANNAN, Frederick W. JACOBSEN, Wayne H. TSUJI
Filed: 28 Sep 22